In Vivo Selection of Plasmodium Falciparum Pfcrt and Pfmdr1 Variants by Artemether-lumefantrine and Dihydroartemisinin-piperaquine in Burkina Faso

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2014 Nov 19

PMID 25403659

Citations 27

Authors

Vito Baraka

Halidou Tinto

Innocent Valea

Robert Fitzhenry

Christopher Delgado-Ratto

Martin K Mbonye

Chantal Van Overmeir

Anna Rosanas-Urgell

Jean-Pierre Van Geertruyden

Umberto DAlessandro

Annette Erhart

Affiliations

Soon will be listed here.

Abstract

Plasmodium falciparum Pfcrt-76 and Pfmdr1-86 gene polymorphisms were determined during a clinical trial in Burkina Faso comparing the efficacies of dihydroartemisinin-piperaquine (DHA-PPQ) and artemether-lumefantrine (AL). Significant selection of Pfcrt-K76 was observed after exposure to AL and DHA-PPQ, as well as selection of Pfmdr1-N86 after AL but not DHA-PPQ treatment, suggesting reverse selection on the Pfcrt gene by PPQ. These results support the rational use of DHA-PPQ in settings where chloroquine (CQ) resistance is high.

Citing Articles

Trend of N86Y and Y184F Mutations in Pfmdr1 Gene in Children Under Seasonal Malaria Chemoprevention Coverage in Nanoro, Burkina Faso.

Millogo K, Kabore B, Sondo P, Compaore E, Kouevi A, Kambou S Acta Parasitol. 2024; 69(4):1967-1976.

PMID: 39356425 PMC: 11649751. DOI: 10.1007/s11686-024-00923-x.

Characterization of Plasmodium Falciparum Resistance Genes to Common Antimalarial Drugs in Semi-urban Areas of Burkina Faso.

Zida A, Tchekounou C, Soulama I, Zongo C, Sombie S, Nikiema S Acta Parasitol. 2024; 69(1):910-921.

PMID: 38478177 DOI: 10.1007/s11686-024-00826-x.

Breaking the cycle of malaria treatment failure.

Boni M Front Epidemiol. 2024; 2:1041896.

PMID: 38455307 PMC: 10910953. DOI: 10.3389/fepid.2022.1041896.

Assessing emergence risk of double-resistant and triple-resistant genotypes of Plasmodium falciparum.

Li E, Nguyen T, Tran T, Zupko R, Boni M Nat Commun. 2024; 15(1):1390.

PMID: 38360803 PMC: 10869733. DOI: 10.1038/s41467-024-45547-x.

Temporal evolution of the resistance genotypes of Plasmodium falciparum in isolates from Equatorial Guinea during 20 years (1999 to 2019).

Berzosa P, Fuente I, Ta-Tang T, Gonzalez V, Garcia L, Rodriguez-Galet A Malar J. 2021; 20(1):463.

PMID: 34906159 PMC: 8670137. DOI: 10.1186/s12936-021-04000-w.

References

Dokomajilar C, Nsobya S, Greenhouse B, Rosenthal P, Dorsey G . Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother. 2006; 50(5):1893-5. PMC: 1472234. DOI: 10.1128/AAC.50.5.1893-1895.2006. View

Some A, Zongo I, Compaore Y, Sakande S, Nosten F, Ouedraogo J . Selection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother. 2014; 58(7):3660-5. PMC: 4068591. DOI: 10.1128/AAC.02406-14. View

Conrad M, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V . Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Dis. 2014; 210(3):344-53. PMC: 4110461. DOI: 10.1093/infdis/jiu141. View

Eastman R, Dharia N, Winzeler E, Fidock D . Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob Agents Chemother. 2011; 55(8):3908-16. PMC: 3147642. DOI: 10.1128/AAC.01793-10. View

Briolant S, Henry M, Oeuvray C, Amalvict R, Baret E, Didillon E . Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Antimicrob Agents Chemother. 2010; 54(9):3537-44. PMC: 2935001. DOI: 10.1128/AAC.00183-10. View

Some A, Sere Y, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B . Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother. 2010; 54(5):1949-54. PMC: 2863637. DOI: 10.1128/AAC.01413-09. View

Danquah I, Coulibaly B, Meissner P, Petruschke I, Muller O, Mockenhaupt F . Selection of pfmdr1 and pfcrt alleles in amodiaquine treatment failure in north-western Burkina Faso. Acta Trop. 2010; 114(1):63-6. DOI: 10.1016/j.actatropica.2009.12.008. View

Nsobya S, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal P . In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother. 2010; 54(3):1200-6. PMC: 2825959. DOI: 10.1128/AAC.01412-09. View

Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C . Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One. 2009; 4(11):e7871. PMC: 2776302. DOI: 10.1371/journal.pone.0007871. View

10.

Mwai L, Kiara S, Abdirahman A, Pole L, Rippert A, Diriye A . In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother. 2009; 53(12):5069-73. PMC: 2786317. DOI: 10.1128/AAC.00638-09. View

11.

Dondorp A, Nosten F, Yi P, Das D, Phyo A, Tarning J . Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361(5):455-67. PMC: 3495232. DOI: 10.1056/NEJMoa0808859. View

12.

Noedl H, Se Y, Schaecher K, Smith B, Socheat D, Fukuda M . Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008; 359(24):2619-20. DOI: 10.1056/NEJMc0805011. View

13.

Sisowath C, Petersen I, Veiga M, Martensson A, Premji Z, Bjorkman A . In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis. 2009; 199(5):750-7. PMC: 2718568. DOI: 10.1086/596738. View

14.

Muangnoicharoen S, Johnson D, Looareesuwan S, Krudsood S, Ward S . Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Antimicrob Agents Chemother. 2009; 53(4):1362-6. PMC: 2663099. DOI: 10.1128/AAC.01656-08. View

15.

Yeka A, Dorsey G, Kamya M, Talisuna A, Lugemwa M, Rwakimari J . Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One. 2008; 3(6):e2390. PMC: 2405936. DOI: 10.1371/journal.pone.0002390. View

16.

Tinto H, Guekoun L, Zongo I, Guiguemde R, DAlessandro U, Ouedraogo J . Chloroquine-resistance molecular markers (Pfcrt T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina Faso. Trop Med Int Health. 2008; 13(2):238-40. DOI: 10.1111/j.1365-3156.2007.01995.x. View

17.

Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A . In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis. 2005; 191(6):1014-7. DOI: 10.1086/427997. View

18.

Davis T, Hung T, Sim I, Karunajeewa H, Ilett K . Piperaquine: a resurgent antimalarial drug. Drugs. 2004; 65(1):75-87. DOI: 10.2165/00003495-200565010-00004. View

19.

Paul R, Packer M, Walmsley M, Lagog M, Ranford-Cartwright L, Paru R . Mating patterns in malaria parasite populations of Papua New Guinea. Science. 1995; 269(5231):1709-11. DOI: 10.1126/science.7569897. View

20.

Tinto H, Ouedraogo J, Erhart A, Van Overmeir C, Dujardin J, Van Marck E . Relationship between the Pfcrt T76 and the Pfmdr-1 Y86 mutations in Plasmodium falciparum and in vitro/in vivo chloroquine resistance in Burkina Faso, West Africa. Infect Genet Evol. 2003; 3(4):287-92. DOI: 10.1016/j.meegid.2003.08.002. View